Journals / Tüberküloz ve Toraks / 2003 / Cilt: 51 - Sayı: 4

The levels of oxidant and antioxidant in patients with COPD

KOAH'lı hastalarda oksidan-antioksidan düzeyleri

Pages
373–379
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We concluded that the use of cigarette increased oxidatiue stress by causing plasma lipid peroxidation and imbalance in erythrocyte antioxidant capacity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:It is determinate that oxidant-antioxidant imbalance is responsible for pathogenesis of chronic obstructive pulmonary dise-ase (COPD) and smoking is playing a part in the pathogenesis.
📊
Key Findings & Data:The leuels of plasma malonyldialdehyde (MDA), erythrocy-te reducted glutathione (GSH) and erythrocyte catalase were studied in 20 patients with COPD, in 20 smokers and in 20 nonsmokers.
💡
Conclusion & Impact:We concluded that the use of cigarette increased oxidatiue stress by causing plasma lipid peroxidation and imbalance in erythrocyte antioxidant capacity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

It is determinate that oxidant-antioxidant imbalance is responsible for pathogenesis of chronic obstructive pulmonary dise-ase (COPD) and smoking is playing a part in the pathogenesis. It was aimed to investigate the oxidant-antioxidant imbalance in smokers and pathogenesis of COPD and their relations with lung functions. This study was done prospectiuely in FÎrat University Medical Faculty, Department of Chest Diseases. The leuels of plasma malonyldialdehyde (MDA), erythrocy-te reducted glutathione (GSH) and erythrocyte catalase were studied in 20 patients with COPD, in 20 smokers and in 20 nonsmokers. All of the cases were male. Pulmonary function tests were done to all cases and the predicted values of FEV1, FVC, and FEV1/FVC were measured. The levels of plasma MDA: 1.44 ± 0.23 nmol/mL, 1.51 ± 0.27 nmol/mL and 1.29 ± 0.13 nmol/mL, the levels of erythrocyte CSH: 0.33 ± 0.13 $$mol/g.Hb, 0.34 ±0.17 $mu$mol/g.Hb and 0.44 ± 0.14 $mu$mol/g.Hb and the levels of catalase were 22.82 ± 17.47 k/g.Hb, 32.88 ± 22.36 k/g.Hb and 55.73 ± 26.56 k/g.Hb in patients with COPD, smokers and healthy nonsmokers respectiuely. There was no significance in each three parameters between smokers and patients with COPD. A significant difference was observed in each three parameters between nonsmokers and patients with COPD (MDA: p= 0.001, GSH: p= 0.028 and catalase: p< 0.001) and between smokers and nonsmokers (MDA: p= 0.035, GSH: p= 0.016 and catalase: p= 0.005). In all three groups, no significant correlation was found between FEV] (predicted %), FEV]/FVC (predicted %) and the ualu.es of erythrocyte catalase, GSH and plasma MDA. In this study, there was an oxidant-antioxidant imbalance systemically in smokers and in patients with COPD. Howeuer, decreasing in the antioxidant capacity and/or increasing in the oxidant capacity either not correlate with spirometric measurements of airway obstruction in smokers or in patients with COPD were observed. We concluded that the use of cigarette increased oxidatiue stress by causing plasma lipid peroxidation and imbalance in erythrocyte antioxidant capacity.

Özet

Oksidan-antioksidanlar arası dengesizliğin kronik obstrüktif akciğer hastalığı (KOAH)'nın patogenezinden sorumlu olduğu, bu dengesizlikte sigara içiminin de rol oynadığı belirtilmektedir. Bu çalışmada, sigara içenlerde ve KOAH patogenezinde oksidan-antioksidan dengesizliği ve akciğer fonksiyonları ile arasındaki ilişkinin araştırılması amaçlandı. Çalışma Fırat Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı'nda prospektif olarak yapıldı. Yirmi KOAH'h, 20 sigara içen ve 20 sigara içmeyen sağlıklı, toplam 60 erkek olguda plazma malonildialdehid (MDA), eritrosit redükte glutatyon (GSH) ve katalaz de-ğerlerine bakıldı. Olgulara solunum fonksiyon testi yapılarak FEV1, FVC, FEV1/FVC değerleri ölçüldü. KOAH'lı, sigara içen ve sigara içmeyen sağlıklı olgularda plazma MDA değerleri sırasıyla 1.44 ± 0.23 nmol/ml, 1.51 ± 0.27 nmol/mL ve 1.29 ± 0.13 nmol/mL, eritrosit GSH değerleri sırasıyla 0.33 ± 0.13$mu$mol/g.Hb, 0.34 ±0.17 $mu$mol/g.Hb ve 0.44 ± 0.14 $mu$mol/g.Hb, katalaz değerleri ise sırasıyla 22.82 ± 17.47 k/g.Hb, 32.88 ± 22.36 k/g.Hb ve 55.73 ± 26.56 k/g.Hb idi. Her üç parametrede de sigara içen olgularla KOAH'lı olgular arasında fark saptanmazken, KOAH'h olgularla sigara içmeyenler arasında (MDA için p= 0.001, GSH için p= 0.028 ve katalaz için p< 0.001) ve sigara içenlerle içmeyen olgular arasında (MDA için p= 0.035, GSH için p= 0.016 ve katalaz için p= 0.005) istatistiksel fark olduğu gözlendi. Üç grupta da FEV1 (% beklenen) ve FEV1/FVC (% beklenen) ile eritrosit katalaz, GSH ve plazma MDA değerleri arasında anlamlı korelasyon bulunamadı. KOAH'h olgularda ve sigara içen kişilerde sistemik olarak oksidan-antioksidan dengesizliği olduğu, ancak antioksidan kapasitedeki azalma ve/veya oksidan kapasitedeki artmanın, hem KOAH'lı hem de sigara içen bireylerde hava yolu obstrüksiyonunun spirometrik ölçümleriyle korele olmadığı gözlendi ve sigara kullanımının plazma lipid peroksidasyonu ve eritrosit antioksidan aktivitede dengesizliğe yol açarak oksidatif stresi arttırdığı sonucuna varıldı.

🔖

Cite This Article

İLHAN, N., ÇELİK, İ., ALTUNTAŞ, E., TURGUT, T., MUZ, M. H., DEVECİ, F. (2022). The levels of oxidant and antioxidant in patients with COPD. Tüberküloz ve Toraks, Cilt: 51 - Sayı: 4, 373–379. https://ajindex.com/articles/619288

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Crystal RG. Oxidants and respiratory tract epithelial injury: Pathogenesis and strategies for therapeutic intervention. Am J Med 1991; 91:39-44
  2. Cohrane CG. Cellular injury by oxidants. Am J Med 1991; 91: 23-9
  3. Kalyoncu AF. Patoloji ve patogenez. Tatlıcıoğlu T (editör). Kronik Obstrûktif Akciğer Hastalığı. Ankara: Güneş Kitabevi, 1996:8-11
  4. Repine JE, Bast A, Lankhorst I and Oxidative Stress Study Group. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 341-57
  5. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isaprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995; 332: 1198-203
  6. Rahman I, MacNee W. Role of antioxldants in smaking-induced lung disease. Free Radical Biology & Medicine 1996; 21: 669-81
  7. MacNee W, Rahman I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:558-65
  8. Anderson R, Theron AJ, Richards GA, et al. Passive smoking by humans sensitizes circulating neutrophils. Am Rev Respir Dis 1991; 144: 570-4
  9. Turner-Warwick M, Kerr IH, Hodson ME, Corrin B. Atlas of radiology of the chest London: Gower Medical Publishing, 1991: 604
  10. Duthie GG, Arthur JR, James WPT. Effects of smoking and vitamin E on blood antioxidant status. Am J Clin Nutr 1991; 53: 1061-3, 11. Beuller E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med 1963; 61: 882-8
  11. Aebi H. Methods of Enzymatic Analysis. In: Bergmeyer U (ed). New York: Academic Press, 1974:673-7
  12. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin Chim Ada 1978; 90: 37-43
  13. Yagi K. Assay of blood plasma or serum. Methods Enzymol 1984; 105: 328-31 15. Şekeroğlu MR, Aslan R, Tarakçıoğlu M ve ark. Sigara kullananlarda lipid peroksidasyonu ue antioksidan aktivite. Tüberküloz ve Toraks 1997; 45: 105-9
  14. Bridges AB, Scott NA, Parry GJ, Belch JJ. Age, sex, cigarette smoking and indices of free radical activity in healthy humans, Eur J Med 1993; 2: 205-8
  15. Liu CS, Wei YH. Age-associated alteration of blood thiol-group-related antioxidants in smokers, Environ Res 1999; 80: 18-24
  16. Lapenna D, De Gioia S, Mezzetti A, et al. Cigarette smoke, ferritin and lipid peroxidation. Am J Respir Crit Care Med 1995; 151: 431-5
  17. Codandabay U, Erythrocyte lipid peroxidation and antioxidants